Skip to main content
    • Aa
    • Aa

Molecular mechanisms of genomic imprinting and clinical implications for cancer

  • Santiago Uribe-Lewis (a1), Kathryn Woodfine (a1), Lovorka Stojic (a1) and Adele Murrell (a1)

Genomic imprinting is an epigenetic marking of genes in the parental germline that ensures the stable transmission of monoallelic gene expression patterns in a parent-of-origin-specific manner. Epigenetic marking systems are thus able to regulate gene activity independently of the underlying DNA sequence. Several imprinted gene products regulate cell proliferation and fetal growth; loss of their imprinted state, which effectively alters their dosage, might promote or suppress tumourigenic processes. Conversely, global epigenetic changes that underlie tumourigenesis might affect imprinted gene expression. Here, we review imprinted genes with regard to their roles in epigenetic predisposition to cancer, and discuss acquired epigenetic changes (DNA methylation, histone modifications and chromatin conformation) either as a result of cancer or as an early event in neoplasia. We also address recent work showing the potential role of noncoding RNA in modifying chromatin and affecting imprinted gene expression, and summarise the effects of loss of imprinting in cancer with regard to the roles that imprinted genes play in regulating growth signalling cascades. Finally, we speculate on the clinical applications of epigenetic drugs in cancer.

Corresponding author
*Corresponding author: Adele Murrell, Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK. E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1T. Cremer and M. Cremer (2010) Chromosome territories. Cold Spring Harbor Perspectives in Biology 2, a003889

2S. Schoenfelder , I. Clay and P. Fraser (2010) The transcriptional interactome: gene expression in 3D. Current Opinion in Genetics and Development 20, 127-133

3T. Kouzarides (2007) Chromatin modifications and their function. Cell 128, 693-705

4P.A. Jones and S.B. Baylin (2007) The epigenomics of cancer. Cell 128, 683-692

5G.J. Filion (2010) Systematic protein location mapping reveals five principal chromatin types in Drosophila cells. Cell 143, 212-224

6J.L. Rinn (2007) Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 129, 1311-1323

7S. Varmuza and M. Mann (1994) Genomic imprinting – defusing the ovarian time bomb. Trends in Genetics 10, 118-123

9A.N. Cheung (2009) Pathogenesis of choriocarcinoma: clinical, genetic and stem cell perspectives. Future Oncology 5, 217-231

10R. Weksberg , C. Shuman and J.B. Beckwith (2010) Beckwith–Wiedemann syndrome. European Journal of Human Genetics 18, 8-14

11J.R. Engel (2000) Epigenotype–phenotype correlations in Beckwith–Wiedemann syndrome. Journal of Medical Genetics 37, 921-926

12K.W. Brown (2008) Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development. Molecular Cancer Research 6, 1114-1123

13A. Murrell (2006) Genomic imprinting and cancer: from primordial germ cells to somatic cells. ScientificWorldJournal 6, 1888-1910

14H.D. Davies (2003) Myeloid leukemia in Prader–Willi syndrome. Jornal de Pediatria 142, 174-178

15D. Kanber (2009) The human retinoblastoma gene is imprinted. PLoS Genetics 5, e1000790

16J. Toguchida (1989) Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma. Nature 338, 156-158

17M.V. Kato (1994) Parental origin of germ-line and somatic mutations in the retinoblastoma gene. Human Genetics 94, 31-38

18A. Schuler (2005) Age at diagnosis of isolated unilateral retinoblastoma does not distinguish patients with and without a constitutional RB1 gene mutation but is influenced by a parent-of-origin effect. European Journal of Cancer 41, 735-740

19A. Kong (2009) Parental origin of sequence variants associated with complex diseases. Nature 462, 868-874

20A. Murrell (2008) Distinct methylation changes at the IGF2-H19 locus in congenital growth disorders and cancer. PLoS One 3, e1849

21C.A. Edwards and A.C. Ferguson-Smith (2007) Mechanisms regulating imprinted genes in clusters. Current Opinion in Cell Biology 19, 281-289

22W. Feng (2008) Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112, 1489-1502

23M.J. Riemenschneider , J. Reifenberger and G. Reifenberger (2008) Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss. International Journal of Cancer 122, 2503-2510

24F. Weber (2005) Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. Journal of Clinical Endocrinology and Metabolism 90, 1149-1155

26T. Kamikihara (2005) Epigenetic silencing of the imprinted gene ZAC by DNA methylation is an early event in the progression of human ovarian cancer. International Journal of Cancer 115, 690-700

27R. Martinez (2009) A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 4, 255-264

28Y. Li , G. Meng and Q.N. Guo (2008) Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Experimental and Molecular Pathology 84, 234-239

29G.A. Ulaner (2003) Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Human Molecular Genetics 12, 535-549

31H.M. Byun (2007) Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Research 67, 10753-10758

32D. Takai (2001) Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Human Molecular Genetics 10, 2619-2626

33J. Wu (2008) Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma. Genomics 91, 443-450

34S. Furukawa (2009) Yolk sac tumor but not seminoma or teratoma is associated with abnormal epigenetic reprogramming pathway and shows frequent hypermethylation of various tumor suppressor genes. Cancer Science 100, 698-708

37K. Hashimoto (1997) Loss of H19 imprinting and up-regulation of H19 and SNRPN in a case with malignant mixed Mullerian tumor of the uterus. Human Pathology 28, 862-865

38C.A. Lynch (2002) Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation. Molecular Cancer 1, 2

39Y. Sun (2006) IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 25, 1042-1052

40T. Kawakami (2006) Erasure of methylation imprint at the promoter and CTCF-binding site upstream of H19 in human testicular germ cell tumors of adolescents indicate their fetal germ cell origin. Oncogene 25, 3225-3236

42E. Yuan (2005) Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Molecular Cancer Research 3, 493-502

43H. Nakagawa (2001) Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 98, 591-596

45S. Honda (2008) Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma. British Journal of Cancer 99, 1891-1899

46X. Li (1998) Promoter-specific methylation and expression alterations of igf2 and h19 are involved in human hepatoblastoma. International Journal of Cancer 75, 176-180

47A. Paradowska (2009) Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia. International Journal of Oncology 35, 87-96

48T. Arima (1997) Association of IGF2 and H19 imprinting with choriocarcinoma development. Cancer Genetics and Cytogenetics 93, 39-47

50Y.W. Cheng (2010) Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer. International Journal of Cancer 127, 568-577

51T. Eriksson (2001) Methylation changes in the human IGF2 p3 promoter parallel IGF2 expression in the primary tumor, established cell line, and xenograft of a human hepatoblastoma. Experimental Cell Research 270, 88-95

52K. Poirier (2003) Loss of parental-specific methylation at the IGF2 locus in human hepatocellular carcinoma. Journal of Pathology 201, 473-479

53M.J. Sullivan (1999) Relaxation of IGF2 imprinting in Wilms tumours associated with specific changes in IGF2 methylation. Oncogene 18, 7527-7534

54Y. Ito (2008) Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Human Molecular Genetics 17, 2633-2643

55Y. Baba (2010) Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology Aug 2; [Epub ahead of print]

56Y. Li (2009) Hypomethylation of the P3 promoter is associated with up-regulation of IGF2 expression in human osteosarcoma. Human Pathology 40, 1441-1447

57J.P. Issa (1996) Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 93, 11757-11762

59O. El-Maarri (2003) Maternal alleles acquiring paternal methylation patterns in biparental complete hydatidiform moles. Human Molecular Genetics 12, 1405-1413

60E. Dejeux (2009) Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss-of-imprinting and overexpression. Endocrine-related Cancer 16, 939-952

61S. Nakano (2006) Expression profile of LIT1/KCNQ1OT1 and epigenetic status at the KvDMR1 in colorectal cancers. Cancer Science 97, 1147-1154

62S.Q. Kuang (2007) Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene 26, 1439-1448

63B.L. Pike (2008) DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia 22, 1035-1043

64D. Astuti (2005) Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. British Journal of Cancer 92, 1574-1580

65T. Kawakami (2006) Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma. Human Molecular Genetics 15, 821-830

66J. Huang (2007) Up-regulation of DLK1 as an imprinted gene could contribute to human hepatocellular carcinoma. Carcinogenesis 28, 1094-1103

67R. Gejman (2008) Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 93, 4119-4125

68L. Benetatos (2008) Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. Clinical Lymphoma and Myeloma 8, 171-175

69L. Benetatos (2010) CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leukemia Research 34, 148-153

70J. Zhao (2005) Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 90, 2179-2186

71S.A. Savage (2007) Analysis of genes critical for growth regulation identifies insulin-like growth factor 2 receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiology, Biomarkers and Prevention 16, 1667-1674

72Z. Huang (2006) High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Research 34, 555-563

73S. Maegawa (2001) Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Molecular Carcinogenesis 31, 1-9

74S. Otsuka (2009) Aberrant promoter methylation and expression of the imprinted PEG3 gene in glioma. Proceedings of the Japan Academy – Series B: Physical and Biological Science 85, 157-165

75S.C. Dowdy (2005) Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecologic Oncology 99, 126-134

76S.J. Kuerbitz (2002) Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia. Carcinogenesis 23, 559-564

77K. Revill (2009) Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma. Endocrine-related Cancer 16, 537-548

78J. Li (2004) Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. Proceedings of the National Academy of Sciences of the United States of America 101, 7341-7346

79S. Kacem and R. Feil (2009) Chromatin mechanisms in genomic imprinting. Mammalian Genome 20, 544-556

80V. Azuara (2006) Chromatin signatures of pluripotent cell lines. Nature Cell Biology 8, 532-538

81D. Monk (2009) Reciprocal imprinting of human GRB10 in placental trophoblast and brain: evolutionary conservation of reversed allelic expression. Human Molecular Genetics 18, 3066-3074

82L.A. Sanz (2008) A mono-allelic bivalent chromatin domain controls tissue-specific imprinting at Grb10. EMBO Journal 27, 2523-2532

83K.R. McEwen and A.C. Ferguson-Smith (2010) Distinguishing epigenetic marks of developmental and imprinting regulation. Epigenetics and Chromatin 3, 2

84A.P. Feinberg and B. Vogelstein (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89-92

85M. Fatemi (2001) The activity of the murine DNA methyltransferase Dnmt1 is controlled by interaction of the catalytic domain with the N-terminal part of the enzyme leading to an allosteric activation of the enzyme after binding to methylated DNA. Journal of Molecular Biology 309, 1189-1199

86J.R. Weaver , M. Susiarjo and M.S. Bartolomei (2009) Imprinting and epigenetic changes in the early embryo. Mammalian Genome 20, 532-543

87X. Li (2008) A maternal-zygotic effect gene, Zfp57, maintains both maternal and paternal imprints. Developmental Cell 15, 547-557

88D.J. Mackay (2008) Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nature Genetics 40, 949-951

89T. Nakamura (2007) PGC7/Stella protects against DNA demethylation in early embryogenesis. Nature Cell Biology 9, 64-71

90C.J. Schoenherr , J.M. Levorse and S.M. Tilghman (2003) CTCF maintains differential methylation at the Igf2/H19 locus. Nature Genetics 33, 66-69

91I. Rhee (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416, 552-556

92S.C. Wu and Y. Zhang (2010) Active DNA demethylation: many roads lead to Rome. Nature Reviews. Molecular Cell Biology 11, 607-620

94M. Tahiliani (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935

95A. Sparmann and M. van Lohuizen (2006) Polycomb silencers control cell fate, development and cancer. Nature Reviews. Cancer 6, 846-856

97R. Cao (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039-1043

98Y.B. Schwartz and V. Pirrotta (2007) Polycomb silencing mechanisms and the management of genomic programmes. Nature Reviews. Genetics 8, 9-22

99J. Wang (2001) Imprinted X inactivation maintained by a mouse polycomb group gene. Nature Genetics 28, 371-375

100R.R. Pandey (2008) Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Molecular Cell 32, 232-246

101R. Terranova (2008) Polycomb group proteins Ezh2 and Rnf2 direct genomic contraction and imprinted repression in early mouse embryos. Developmental Cell 15, 668-679

102L. Redrup (2009) The long noncoding RNA Kcnq1ot1 organises a lineage-specific nuclear domain for epigenetic gene silencing. Development 136, 525-530

103A.P. Bracken and K. Helin (2009) Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nature Reviews. Cancer 9, 773-784

104D. Pasini (2008) Regulation of stem cell differentiation by histone methyltransferases and demethylases. Cold Spring Harbor Symppsia on Quantitative Biology 73, 253-263

105J.E. Ohm (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nature Genetics 39, 237-242

106E. Vire (2006) The polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874

107V.K. Tiwari (2008) A novel 6C assay uncovers Polycomb-mediated higher order chromatin conformations. Genome Research 18, 1171-1179

108A. Smallwood (2007) Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes and Development 21, 1169-1178

109P.O. Esteve (2006) Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes and Development 20, 3089-3103

110M. Tachibana (2008) G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription. EMBO Journal 27, 2681-2690

111A. Wagschal (2008) G9a histone methyltransferase contributes to imprinting in the mouse placenta. Molecular and Cellular Biology 28, 1104-1113

112T. Nagano (2008) The air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science 322, 1717-1720

113J. Ueda (2006) Zinc finger protein Wiz links G9a/GLP histone methyltransferases to the co-repressor molecule CtBP. Journal of Biological Chemistry 281, 20120-20128

114J. Huang (2010) G9a and Glp methylate lysine 373 in the tumor suppressor p53. Journal of Biological Chemistry 285, 9636-9641

115M. Pannetier (2008) PR-SET7 and SUV4-20H regulate H4 lysine-20 methylation at imprinting control regions in the mouse. EMBO Report 9, 998-1005

116S.J. Nielsen (2001) Rb targets histone H3 methylation and HP1 to promoters. Nature 412, 561-565

117R.G. Sewalt (2002) Selective interactions between vertebrate polycomb homologs and the SUV39H1 histone lysine methyltransferase suggest that histone H3-K9 methylation contributes to chromosomal targeting of polycomb group proteins. Molecular and Cellular Biology 22, 5539-5553

118P. Frontelo (2004) Suv39h histone methyltransferases interact with Smads and cooperate in BMP-induced repression. Oncogene 23, 5242-5251

119A.H. Peters (2001) Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107, 323-337

120P.M. Ayton and M.L. Cleary (2001) Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20, 5695-5707

121A. Patel (2009) On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex. Journal of Biological Chemistry 284, 24242-24256

122P.O. Esteve (2009) Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America 106, 5076-5081

123D.N. Ciccone (2009) KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints. Nature 461, 415-418

124Y. Wang (2009) LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138, 660-672

125Y. Zhang (1999) Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes and Development 13, 1924-1935

126K.J. Reese (2007) Maintenance of paternal methylation and repression of the imprinted H19 gene requires MBD3. PLoS Genetics 3, e137

127R.J. Klose (2007) The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell 128, 889-900

128G. Schotta (2004) A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes and Development 18, 1251-1262

129K. Nishioka (2002) PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Molecular Cell 9, 1201-1213

130M.F. Fraga (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics 37, 391-400

131V.P. Tryndyak , O. Kovalchuk and I.P. Pogribny (2006) Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biology and Therapy 5, 65-70

132M.Y. Wu , T.F. Tsai and A.L. Beaudet (2006) Deficiency of Rbbp1/Arid4a and Rbbp1l1/Arid4b alters epigenetic modifications and suppresses an imprinting defect in the PWS/AS domain. Genes and Development 20, 2859-2870

133Q. Zhao (2009) PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nature Structural and Molecular Biology 16, 304-311

134P. Jelinic , J.C. Stehle and P. Shaw (2006) The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation. PLoS Biology 4, e355

135R. Ohlsson , V. Lobanenkov and E. Klenova (2010) Does CTCF mediate between nuclear organization and gene expression? Bioessays 32, 37-50

136P. Nguyen (2008) CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region. Cancer Research 68, 5546-5551

137D. Zilberman (2008) Histone H2A.Z and DNA methylation are mutually antagonistic chromatin marks. Nature 456, 125-129

138A. Barski (2007) High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837

140J.H. Choo (2006) Allele-specific deposition of macroH2A1 in imprinting control regions. Human Molecular Genetics 15, 717-724

141T.P. Rasmussen (1999) Messenger RNAs encoding mouse histone macroH2A1 isoforms are expressed at similar levels in male and female cells and result from alternative splicing. Nucleic Acids Research 27, 3685-3689

142R. Zhang (2005) Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Developmental Cell 8, 19-30

143J.C. Sporn (2009) Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene 28, 3423-3428

144R. Nativio (2009) Cohesin is required for higher-order chromatin conformation at the imprinted IGF2-H19 locus. PLoS Genetics 5, e1000739

145T.H. Vu , A.H. Nguyen and A.R. Hoffman (2010) Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells. Human Molecular Genetics 19, 901-919

147T. Mishiro (2009) Architectural roles of multiple chromatin insulators at the human apolipoprotein gene cluster. EMBO Journal 28, 1234-1245

148R.J. Taft (2010) Non-coding RNAs: regulators of disease. Journal of Pathology 220, 126-139

149K. Ng (2007) Xist and the order of silencing. EMBO Report 8, 34-39

150F. Sleutels , R. Zwart and D.P. Barlow (2002) The non-coding Air RNA is required for silencing autosomal imprinted genes. Nature 415, 810-813

151N. Thakur (2004) An antisense RNA regulates the bidirectional silencing property of the Kcnq1 imprinting control region. Molecular and Cellular Biology 24, 7855-7862

152C.M. Williamson (2006) Identification of an imprinting control region affecting the expression of all transcripts in the Gnas cluster. Nature Genetics 38, 350-355

153E. Le Meur (2005) Dynamic developmental regulation of the large non-coding RNA associated with the mouse 7C imprinted chromosomal region. Developmental Biology 286, 587-600

154J. Peters and J.E. Robson (2008) Imprinted noncoding RNAs. Mammalian Genome 19, 493-502

155P.A. Latos and D.P. Barlow (2009) Regulation of imprinted expression by macro non-coding RNAs. RNA Biology 6, 100-106

156X. Wang (2008) Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 454, 126-130

157Q.J. Hudson (2010) Genomic imprinting mechanisms in embryonic and extraembryonic mouse tissues. Heredity 105, 45-56

158W. Yu (2008) Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 451, 202-206

159K.V. Morris (2008) Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. PLoS Genetics 4, e1000258

160T. Watanabe (2008) Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes. Nature 453, 539-543

161O.H. Tam (2008) Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature 453, 534-538

162M. Guttman (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458, 223-227

163A.M. Khalil (2009) Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proceedings of the National Academy of Sciences of the United States of America 106, 11667-11672

164R.A. Gupta (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071-1076

165T. Yoshimizu (2008) The H19 locus acts in vivo as a tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America 105, 12417-12422

166W.P. Tsang (2010) Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 31, 350-358

167Y. Zhou (2007) Activation of p53 by MEG3 non-coding RNA. Journal of Biological Chemistry 282, 24731-24742

168X. Zhang (2010) Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology 151, 939-947

169D. Baek (2008) The impact of microRNAs on protein output. Nature 455, 64-71

170H. Seitz (2004) A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Research 14, 1741-1748

171E.A. Glazov (2008) Origin, evolution, and biological role of miRNA cluster in DLK-DIO3 genomic region in placental mammals. Molecular Biology and Evolution 25, 939-948

172Y. Saito (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9, 435-443

173J.W. Lee (2008) Altered MicroRNA expression in cervical carcinomas. Clinical Cancer Research 14, 2535-2542

174J. Yu (2006) Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochemical and Biophysical Research Communications 349, 59-68

175L. Guo (2010) Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. European Journal of Cancer 46, 1692-1702

176M. Guled (2009) CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma – a miRNA microarray analysis. Genes, Chromosomes and Cancer 48, 615-623

177A. Veronese (2010) Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Research 70, 3140-3149

179T.S. Wong (2008) Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clinical Cancer Research 14, 2588-2592

180C. Liu (2010) Epigenetic regulation of miR-184 by MBD1 governs neural stem cell proliferation and differentiation. Cell Stem Cell 6, 433-444

181M. Stubbs and J.R. Griffiths (2010) The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Advances in Enzyme Regulation 50, 44-55

182W. Timp , A. Levchenko and A.P. Feinberg (2009) A new link between epigenetic progenitor lesions in cancer and the dynamics of signal transduction. Cell Cycle 8, 383-390

183A.R. Young and M. Narita (2009) SASP reflects senescence. EMBO Report 10, 228-230

184N. Tezuka , A.M. Brown and S. Yanagawa (2007) GRB10 binds to LRP6, the Wnt co-receptor and inhibits canonical Wnt signaling pathway. Biochemical and Biophysical Research Communications 356, 648-654

185X. Jiang (2010) The imprinted gene PEG3 inhibits Wnt signaling and regulates glioma growth. Journal of Biological Chemistry 285, 8472-8480

186S. Kobayashi (2002) Paternal expression of a novel imprinted gene, Peg12/Frat3, in the mouse 7C region homologous to the Prader–Willi syndrome region. Biochemical and Biophysical Research Communications 290, 403-408

187A.M. Jubb (2006) Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia. Oncogene 25, 3445-3457

188W. Zhu (2008) IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis. Nature 454, 345-349

189K.R. Wick (2003) Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the association of IRS-1/IRS-2 with the insulin receptor. Journal of Biological Chemistry 278, 8460-8467

190P. Langlais (2004) Negative regulation of insulin-stimulated mitogen-activated protein kinase signaling by Grb10. Molecular Endocrinology 18, 350-358

191M. Charalambous (2010) Maternally-inherited Grb10 reduces placental size and efficiency. Developmental Biology 337, 1-8

192M.P. Playford (2000) Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proceedings of the National Academy of Sciences of the United States of America 97, 12103-12108

193M. Wade , Y.V. Wang and G.M. Wahl (2010) The p53 orchestra: Mdm2 and Mdmx set the tone. Trends in Cell Biology 20, 299-309

194M. Kaghad (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819

195J.W. Kim (2008) TIP60 represses transcriptional activity of p73beta via an MDM2-bridged ternary complex. Journal of Biological Chemistry 283, 20077-20086

196Y. Yu (2006) Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. Methods in Enzymology 407, 455-468

197A. Nishimoto (2005) A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Research 65, 6701-6710

198S. Huang (2010) ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Bioscience Reports 30, 159-168

199D. Ferres-Marco (2006) Epigenetic silencers and Notch collaborate to promote malignant tumours by Rb silencing. Nature 439, 430-436

200S.J. Bray (2008) The atypical mammalian ligand Delta-like homologue 1 (Dlk1) can regulate Notch signalling in Drosophila. BMC Developmental Biology 8, 11

201H. Ikushima and K. Miyazono (2010) TGFbeta signalling: a complex web in cancer progression. Nature Reviews. Cancer 10, 415-424

202R. Bergstrom (2010) Transforming growth factor beta promotes complexes between Smad proteins and CTCF on the H19 imprinting control region chromatin. Journal of Biological Chemistry 285, 19727-19737

203J.M. Scandura (2004) Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proceedings of the National Academy of Sciences of the United States of America 101, 15231-15236

204A. Lux (2005) Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1. Journal of Biological Chemistry 280, 8482-8493

205C.M. Li (2006) PEG10 is a c-MYC target gene in cancer cells. Cancer Research 66, 665-672

207P. Zhang (1998) Cooperation between the Cdk inhibitors p27(KIP1) and p57(KIP2) in the control of tissue growth and development. Genes and Development 12, 3162-3167

208S.B. Montgomery (2010) Transcriptome genetics using second generation sequencing in a Caucasian population. Nature 464, 773-777

209M.A. Dawson (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461, 819-822

210Y. Saito and P.A. Jones (2006) Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 5, 2220-2222

211R.B. Klisovic (2008) A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clinical Cancer Research 14, 2444-2449

212C. Ptak and A. Petronis (2008) Epigenetics and complex disease: from etiology to new therapeutics. Annual Review of Pharmacology and Toxicology 48, 257-276

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *